Beyond Innovations For Life
We have been committed to developing novel antibody therapeutics since the company was founded in 2008 and was successfully listed on KOSDAQ in 2018. Our goal is to focus on the development of novel antibody therapeutics and become a leading biotech company that contributes to human health and well-being
History
Dec.
◦ FPFV(First Patient First Visit) of phase 2 study of Olinvacimab/Pembrolizumab combo treatment for mTNBC patients in Australia
◦ PharmAbcine’s next-generation bispecific antibody drug discovery project wins a New Drug Development Fund from the government
Sep.
◦ PMC-309 to receive government grant from KDDF
◦ PharmAbcine submits joint patent application with MSD for the Treatment of Cancer
◦ PharmAbcine receives the ‘Best Poster Award’ for PMC-309 presentation at orean Society of Medical Oncology (KSMO) 2021
◦ Australia HREC approval of Phase 2 Olinvacimab/Pembrolizumab combination trial in mTNBC
Apr.
◦ PharmAbcine signs clinical trial collaboration with MSD Phase 2 Olinvacimab/Pembrolizumab combination trial in mTNBC
Jan.
◦ PharmAbcine announces a research collaboration with LegoChem Biosciences
Dec.
◦ PharmAbcine to present new interim data from its ongoing mTNBC trial at SABCS 2020
◦ Certification of Excellent Corporation R&D Center(ECRC)
Nov.
◦ PharmAbcine to present the final data of Phase 2a rGBM trial at SNO 2020
Sep.
◦ PharmAbcine unveils Olinvacimab's positive results from Phase 1b studies at KSMO 2020
◦ PMC-403 and PMC-309 win Poster Award at Korean Society of Medical Oncology(KSMO) 2020
Aug.
◦ PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS
◦ PharmAbcine expands partnership with Samsung Biologics for PMC-403
◦ PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology(SLBio) to evaluate a combination therapy to treat NSCLC
Jun.
◦ PharmAbcine signs a long-term Contract Manufacturing Organization Agreement for Olinvacimab with Binex
◦ PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309
Apr.
◦ PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
◦ Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment
Jan.
◦ Company incorporation in the U.S
Nov.
◦ FPFV(First Patient First Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment
Sep.
◦ FPFV(First Patient First Visit) of phase 2 study of Olinvacimab treatment for rGBM patients who have progressed after bevacizumab treatment
Aug.
◦ US IRB(Stanford Hospital) approval of Olinvacimab phase 2 study for the treatment of rGBM patients who have progressed after Bevacizumab treatment
◦ Australia HREC approval of Olinvacimab Phase 2 study for the treatment of rGBM patients who have progressed after Bevacizumab treatment
May.
◦ Issuance of CB(KRW 100 Billion)
◦ PharmAbcine enters into a development and manufacturing partnership with Thermo Fisher for PMC-309
Jan.
◦ FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of rGBM patients
◦ FPFV(First patient First visit) on the study of Olinvacimab/Pembrolizumab combination trial for the treatment of mTNBC patients
Dec.
◦ Phase 1b Olinvacimab/Pembrolizumab combination trials for both rGBM and mTNBC open for recruitment in Australia
Nov.
◦ November 21, 2018 / KOSDAQ listed
◦ Company incorporation in Australia
Oct.
◦ Orphan drug development appointed
Sep.
◦ Approval of Olinvacimab Phase 2 IND for rGBM patient who has progressed after Bevacizumab treatment
◦ Biologics Award
Mar.
◦ ODD approval of Olinvacimab for rGBM
Jan.
◦ PharmAbcine signs a Clinical Research Collaboration Agreement with MSD for Olinvacimab/Pembrolizumab combination trials
Jun.
◦ Completion of Olinvacimab Phase 2a trial for rGBM Patients
Apr.
◦ Commendation from KHIDI
Jun.
◦ Commendation from KFDS
Feb.
◦ Start of Olinvacimab Phase 2a for rGBM Patients
Oct.
◦ Olinvacimab receives National R&D Award and chosen as the best among 100 accomplishments in 2015 by Ministry of Science and ICT
Sep.
◦ Nominated as Korea Brain Power Company in 2015
Dec.
◦ Out-Licensing PMC-001
◦ Health and Medical Technology Development Business Award(CEO)
Nov.
◦ Award from the Minister from KMTIE
- Distinguished Industrial Engineer(CEO)
- Technology Commercialization(CFO)
Oct.
◦ Out-Licensing of Olinvacimab
Jul.
◦ Out-Licensing of PMC-001
Jun.
◦ Tech-Connect National Innovation Award
May.
◦ Korea Eureka Day Award 2014
Mar.
◦ Out-Licensing of Olinvacimab
◦ Selected as INNOBIZ company
Oct.
◦ Ministry of Education Award
Sep.
◦ Completion of Olinvacimab Phase 1
Mar.
◦ Out-Licensed of 1E4 mAb
Nov.
◦ Research collaboration with Sanofi-Aventis
Apr.
◦ Pharma -Idol Award from 7th Annual China Pharmaceutical R&D Summit Conference
Nov.
◦ Start of Olinvacimab (TTAC-0001, formerly known as tanibirumab) Phase 1
Sep.
◦ Green Technology Citification
Jul.
◦ Olinvacimab (TTAC-0001, formerly known as
tanibirumab) IND approved
Dec.
◦ R&D Center affiliated
Sep.
◦ Designation of foreign investment company
Mar.
◦ Certificated as venture business
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
HQ +82-42-863-2017
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVE